Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Medicus Pharma Ltd. - Common Stock (NQ:MDCX)

3.045 -0.235 (-7.16%)
Delayed Quote Updated: 12:27 PM EDT, Oct 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Medicus Pharma Ltd. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Friday's after hours session: top gainers and losers ↗
Via Chartmill
These stocks are moving in today's pre-market session ↗
Via Chartmill
Top stock movements in today's session. ↗
Via Chartmill
Let's take a look at the stocks that are in motion in today's session. ↗
Via Chartmill
Traders are paying attention to the gapping stocks in Thursday's session. ↗
Via Chartmill
Thursday's pre-market session: top gainers and losers ↗
Via Chartmill
News headline image
Medicus Pharma Highlights Three Years of Progress and Outlines Potential Path to Long Term Value
Advancing Precision Oncology and Partner-Ready Therapeutic Programs Through Capital-Efficient Development 
From Medicus Pharma Ltd
Via GlobeNewswire
What's going on in today's after hours session ↗
Via Chartmill
News headline image
Medicus Pharma Submits Optimized Teverelix® Registrational Protocol to FDA to Create Partner Ready Program in Advanced Prostate Cancer
Proposed seamless design would incorporate previously FDA-cleared dose-optimization work into a single registration-intent program aligning it with Company’s capital-efficient development strategy 
From Medicus Pharma Ltd
Via GlobeNewswire
News headline image
Medicus Pharma Announces Exclusive Development Focus for SkinJect® in Gorlin Syndrome Following Commercial, Clinical and Regulatory Assessment
Decision advances Company’s previously announced capital-efficient development strategy by concentrating resources on FDA-authorized, SKNJCT-005, NDA-enabling, Registrational Phase 2b Study in Gorlin... 
From Medicus Pharma Ltd
Via GlobeNewswire
Unusual volume stocks are being observed in Thursday's session. ↗
Via Chartmill
News headline image
Medicus Pharma Publishes Abridged Final Phase 2 SkinJect® Clinical Study Report (CSR) Results Identifying 200 µg D-MNA Patch as the Lead Development Dose
CSR provides a clinical foundation for the Company’s recently announced capital-efficient focus on FDA-authorized Gorlin Syndrome NDA-enabling development program while supporting partnership... 
From Medicus Pharma Ltd
Via GlobeNewswire
Unusual volume stocks in Tuesday's session ↗
Via Chartmill
News headline image
Medicus Pharma Advances Transformation into a Precision Oncology-Led Biotechnology Company
Company prioritizes CD228V precision oncology development in Melanoma while pursuing capital-efficient partnerships for SkinJect® and Teverelix® indications 
From Medicus Pharma Ltd
Via GlobeNewswire
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗
Via Chartmill
Check out the stocks that are attracting the most attention and driving market activity. ↗
Via Chartmill
Thursday's session: top gainers and losers ↗
Via Chartmill
Gapping stocks in Thursday's session ↗
Via Chartmill
Wondering what's happening in today's pre-market session? ↗
Via Chartmill
News headline image
Medicus Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update
From Medicus Pharma Ltd
Via ACCESS Newswire
News headline image
Medicus Pharma Appoints Dr. Faisal Mehmud as Chief Executive Officer of Antev Limited, United Kingdom
Dr. Mehmud’s appointment further aligns the scientific, clinical, regulatory and operational leadership of Antev 
From Medicus Pharma Ltd
Via GlobeNewswire
News headline image
Medicus Pharma Receives UAE Department of Health (DOH) Authorization to proceed with Novel Prospective Genomics Guided Precision Medicine Study Evaluating Teverelix® in Women with Endometriosis
Randomized Phase 2a PRECISION-E2 study designed to evaluate a predefined panel of genes to advance personalized medicine in women's health 
From Medicus Pharma Ltd
Via GlobeNewswire
News headline image
Medicus Pharma Receives FDA “Study May Proceed” Letter for NDA-Enabling Registrational SkinJect® Study in Patients with Gorlin Syndrome
SKNJCT-005 registrational clinical study protocol strengthened through planned implementation of FDA recommendations, including combined clinical and histological clearance endpoints and extended... 
From Medicus Pharma Ltd
Via GlobeNewswire
News headline image
New to The Street to Broadcast Nationwide on Bloomberg Television Tonight at 6:30 PM ET Featuring RHINO Bitcoin, Marina Decisions, Medicus Pharma and Virtuix Holdings
From New to The Street
Via ACCESS Newswire
Top movers in Friday's after hours session ↗
Via Chartmill
News headline image
Medicus Pharma Receives Positive FDA Feedback and Central IRB Approval for Optimized Phase 2 Teverelix® Novel Study in Acute Urinary Retention
Regulatory and ethical-review milestones advance a capital-efficient Phase 2 study expected to enroll ~126 patients versus ~390 under the previously disclosed development plan 
From Medicus Pharma Ltd
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
Gainers Shuttle Pharmaceuticals (NASDAQ:SHPH) shares rose 56.1% to $4.62 during Monday's after-market session. The company's market cap stands at $1.7 million. Medicus Pharma (NASDAQ:MDCX) stock rose... 
Via Benzinga
Curious about the stocks that are showing activity after the closing bell on Monday? ↗
Via Chartmill
News headline image
New to The Street Show #760 Airs Tonight on Bloomberg Television Across the U.S. on Independence Day Featuring Sullivan & Cromwell’s Frank Aquila, Medicus Pharma, PetVivo, FreeCast and YY Group
From New to The Street
Via ACCESS Newswire
News headline image
Medicus Pharma to Showcase SkinJect® Registrational Strategy and Teverelix® Precision Medicine Program at Bio International 2026
Company’s presentation will provide updates on SkinJect® Phase 2b Pivotal Study in patients with Gorlin Syndrome and Teverelix® Groundbreaking PRECISION-E2 Phase 2a Endometriosis Study leveraging the... 
From Medicus Pharma Ltd
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.